VX-222 is a novel, potent and selective inhibitor of non-nucleoside polymerase of the hepatitis C virus (HCV) RNA-dependent RNA polymerase, with an IC50 range of 0.94-1.2 µM. VX-222 selectively inhibits the replication of both HCV1a and HCV1b.